Imaging collagen in early interstitial lung disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of the PET imaging probe [68Ga]CBP8 in detecting collagen deposition in patients with early interstitial lung disease. The probe selectively binds to collagen type I, which is crucial in the development of pulmonary fibrosis. The study aims to determine if [68Ga]CBP8-PET imaging can identify increased collagen levels and if the uptake of the probe can predict disease progression. Participants include first-degree relatives of pulmonary fibrosis patients and individuals with interstitial lung abnormalities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Group 1: First degree relatives of a family member with pulmonary fibrosis (n=8)

* Age greater than 40 years
* Have the ability to give written informed consent
* First degree relative of a family member with pulmonary fibrosis
* No known history of interstitial lung disease
* No tobacco use within the prior 6 months.

Group 2: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) (n=22)

* Age greater than 40 years
* Have the ability to give written informed consent
* ILAs or early ILD (defined by presence of reticular markings and / or traction bronchiectasis but absence of a definite UIP pattern)
* No tobacco use within the prior 6 months.

Exclusion criteria:

* Electrical implants such as cardiac pacemaker or perfusion pump
* Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants ferromagnetic objects such as jewelry or metal clips in clothing
* Historical eGFR of less than 30 mL/min/1.73 m2
* Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test is required for females having child-bearing potential before the subject can participate)
* Claustrophobic reactions
* Research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months)
* Unable to lie comfortably on a bed inside the MR-PET
* BMI \> 33 (limit of the PET-MRI table)
* Determined by the investigator(s) to be clinically unsuitable for the study (e.g. based on screening visit and/or during study procedures)
* Pneumonia or other acute respiratory illness within 6 weeks of study entry
* Parenchymal lung disease except for ILD/ILAs or emphysema
* Acute exacerbation of ILD within the prior 6 months
* VATS within the prior 6 months
* Prior radiation therapy to the thorax
* Known allergy to gadolinium.

Where it's running

• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Sydney B Montesi, MD
• Email: sbmontesi@partners.org
• Phone: 617-724-4030

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Telitacicept for primary Sjögren’s with interstitial lung disease

  This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.

  Recruiting Peking University People's Hospital · Beijing · NCT07843381

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis

  A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.

  Recruiting Phase 3 Insmed Incorporated · DuBois, Pennsylvania · NCT07805785

• Treatment Response in Myositis-Associated RP-ILD in Adults

  This study tests how people with myositis and rapidly progressing interstitial lung disease respond to an immunosuppressant treatment approach.

  Recruiting Singapore General Hospital · Singapore · NCT07775235

• AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT

  This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.

  Recruiting Taichung Veterans General Hospital · Taichung · NCT07761377

• See if 18F-FAPI-74 PET/CT can better detect fibrosis in heart and lung disease

  Researchers are testing a new PET/CT tracer, 18F-FAPI-74, to see if it can reveal early fibrotic changes in people with heart and lung diseases who are at risk for tissue scarring.

  Recruiting Phase 3 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07613099

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.